In Brief: OTC emergency eyewash meeting, FDA official to Perrigo, e-cigarette regulation urged, emerging markets key for J&J in OTC
This article was originally published in The Tan Sheet
Executive Summary
FDA seeks OTC emergency eyewash input; CDER office head moves to Perrigo; Lawmakers, medical groups urge e-cigarette regulation; J&J eyes emerging markets for OTC business; more news In Brief.
You may also be interested in...
Jenkins' Retirement From US FDA Was Several Years In The Making
Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.
J&J Prioritizes OTC Return With McNeil Remediation End In Sight
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”